Erratum: Preclinical activity of gefitinib in non-keratinizing nasopharyngeal carcinoma cell lines and biomarkers of response (Investigational New Drugs DOI: 10.1007/s10637-009-9316-7);Preclinical activity of gefitinib in non-keratinizing nasopharyngeal carcinoma cell lines and biomarkers of response

Investigational New Drugs

Volumn 28, Issue 3, 2010, Pages 326-333

  Ma, Brigette B Y ^a,b   Lui, Vivian W Y ^a   Poon, Fan Fong ^a   Wong, S C Cesar ^a   To, Ka Fai ^b   Wong, Elaine ^a   Chen, Honglin ^c   Lo, Kwok Wai ^a   Tao, Qian ^a   Chan, Anthony T C ^a  

^a CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

^b CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

^c UNIVERSITY OF HONG KONG   (Hong Kong)

Author keywords

Epidermal growth factor receptor; Gefitinib; Head and neck cancer

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; GEFITINIB; K RAS PROTEIN; MITOGEN ACTIVATED PROTEIN KINASE; PROTEIN KINASE B; STAT3 PROTEIN;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL CULTURE; CANCER INHIBITION; CANCER INVASION; CANCER RESISTANCE; CELL CYCLE ARREST; CELL CYCLE G1 PHASE; CONTROLLED STUDY; DRUG RESPONSE; DRUG SENSITIVITY; ENZYME ACTIVATION; GENE AMPLIFICATION; GENE MUTATION; HUMAN; HUMAN CELL; IC 50; NASOPHARYNX CARCINOMA; PRIORITY JOURNAL; PROTEIN EXPRESSION;

EID: 77952242739     PISSN: 01676997     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10637-010-9397-3     Document Type: Erratum

References (22)

1. Q Tao AT Chan 2007 Nasopharyngeal carcinoma: molecular pathogenesis and therapeutic developments Expert Rev Mol Med 9 1 24 10.1017/S1462399407000312 17477889 (Pubitemid 47398642)
2. B Ma T Poon KF To PML Teo ML Chan KF Mo B Ma MP Lai S Ho ATC Chan 2003 Expression and prognostic significance of epidermal growth factor receptor and HER2 protein in nasopharyngeal carcinoma Head Neck 25 864 872 10.1002/hed.10307 12966511 (Pubitemid 37139899)
3. FL Sung TC Poon EP Hui BB Ma E Liong KF To DP Huang AT Chan 2005 Antitumor effect and enhancement of cytotoxic drug activity by cetuximab in nasopharyngeal carcinoma cells In Vivo 19 237 245 1:CAS:528:DC%2BD2MXjtFyisLc%3D 15796181
4. AT Chan MM Hsu BC Goh EP Hui TW Liu MJ Millward RL Hong J Whang-Peng BB Ma KF To M Mueser N Amellal X Lin AY Chang 2005 Multicenter, phase II study of cetuximab in combination with carboplatin in patients with recurrent or metastatic nasopharyngeal carcinoma J Clin Oncol 23 3568 3576 10.1200/JCO.2005.02.147 1:CAS:528:DC%2BD2MXlsVyhs7w%3D 15809453
5. B Ma EP Hui A King KF To F Mo SF Leung M Kam YM Lo B Zee T Mok A Ahuja AT Chan 2008 A phase II study of gefitinib patients with metastatic or locoregionally recurrent nasopharyngeal carcinoma and evaluation of plasma Epstein-Barr virus DNA as a biomarker of efficacy Cancer Chemother Pharmacol 62 59 64 10.1007/s00280-007-0575-8 1:CAS:528:DC%2BD1cXks1KrsLo%3D 17762933 (Pubitemid 351537846)
6. VW Lui AL Boehm P Koppikar RJ Leeman D Johnson M Ogagan E Childs M Freilino JR Grandis 2007 Antiproliferative mechanisms of a transcription factor decoy targeting signal transducer and activator of transcription (STAT) 3: the role of STAT1 Mol Pharmacol 71 1435 1443 10.1124/mol.106.032284 1:CAS:528:DC%2BD2sXlslSis7c%3D 17325127 (Pubitemid 46658696)
7. TJ Seng JS Low H Li Y Cui HK Goh ML Wong G Srivastava D Sidransky J Califano RD Steenbergen SY Rha J Tan WS Hsieh RF Ambinder X Lin AT Chan Q Tao 2007 The major 8p22 tumor suppressor DLC1 is frequently silenced by methylation in both endemic and sporadic nasopharyngeal, esophageal, and cervical carcinomas, and inhibits tumor cell colony formation Oncogene 26 934 944 10.1038/sj.onc.1209839 1:CAS:528:DC%2BD2sXhsVersbs%3D 16862168
8. J Adelaide P Finetti I Bekhouche L Repellini J Geneix F Sircoulomb E Charafe-Jauffret N Cervera J Desplans D Parzy E Schoenmakers P Viens J Jacquemier D Birnbaum F Bertucci M Chaffanet 2007 Integrated profiling of basal and luminal breast cancers Cancer Res 67 11565 11575 10.1158/0008-5472.CAN-07- 2536 1:CAS:528:DC%2BD2sXhsVCjs73F 18089785
9. M Hopfner AP Sutter A Huether D Schuppan M Zeitz H Scherubl 2004 Targeting the epidermal growth factor receptor by gefitinib for treatment of hepatocellular carcinoma J Hepatol 41 1008 1016 10.1016/j.jhep.2004.08.024 15582135 (Pubitemid 39575669)
10. L Bonaccorsi V Carloni M Muratori L Formigli S Zecchi G Forti E Baldi 2004 EGF receptor (EGFR) signaling promoting invasion is disrupted in androgen-sensitive prostate cancer cells by an interaction between EGFR and androgen receptor (AR) Int J Cancer 112 78 86 10.1002/ijc.20362 1:CAS:528:DC%2BD2cXnvVWlsbw%3D 15305378 (Pubitemid 39249494)
11. C Festuccia GL Gravina D Millimaggi P Muzi S Speca E Ricevuto C Vicentini M Bologna 2007 Uncoupling of the epidermal growth factor receptor from downstream signal transduction molecules guides the acquired resistance to gefitinib in prostate cancer cells Oncol Rep 18 503 511 1:CAS:528: DC%2BD2sXpsFGlu7Y%3D 17611677
12. SW Han PG Hwang DH Chung DW Kim SA Im YT Kim TY Kim DS Heo YJ Bang NK Kim 2005 Epidermal growth factor receptor (EGFR) downstream molecules as response predictive markers for gefitinib (Iressa, ZD1839) in chemotherapy-resistant non-small cell lung cancer Int J Cancer 113 109 115 10.1002/ijc.20550 1:CAS:528:DC%2BD2cXhtVWgsL7P 15386420 (Pubitemid 39507317)
13. B Li CM Chang M Yuan WG McKenna HK Shu 2003 Resistance to small molecule inhibitors of epidermal growth factor receptor in malignant gliomas Cancer Res 63 7443 7450 1:CAS:528:DC%2BD3sXovVGltb8%3D 14612544
14. AB Hui KW Lo PM Teo KF To DP Huang 2002 Genome wide detection of oncogene amplifications in nasopharyngeal carcinoma by array based comparative genomic hybridization Int J Oncol 20 467 473 1:CAS:528:DC%2BD38XitVChu74%3D 11836556
15. T Takano Y Ohe H Sakamoto K Tsuta Y Matsuno U Tateishi S Yamamoto H Nokihara N Yamamoto I Sekine H Kunitoh T Shibata T Sakiyama T Yoshida T Tamura 2005 Epidermal growth factor receptor gene mutations and increased copy numbers predict gefitinib sensitivity in patients with recurrent non-small-cell lung cancer J Clin Oncol 23 6829 6837 10.1200/JCO.2005.01.0793 1:CAS:528: DC%2BD2MXhtFCrsb3P 15998907
16. L Ferrer-Soler A Vazquez-Martin J Brunet JA Menendez R De Llorens R Colomer 2007 An update of the mechanisms of resistance to EGFR-tyrosine kinase inhibitors in breast cancer: Gefitinib (Iressa)-induced changes in the expression and nucleo-cytoplasmic trafficking of HER-ligands (Review) Int J Mol Med 20 3 10 1:CAS:528:DC%2BD2sXot1Kqt74%3D 17549382
17. MS Pino M Shrader CH Baker F Cognetti HQ Xiong JL Abbruzzese DJ McConkey 2006 Transforming growth factor alpha expression drives constitutive epidermal growth factor receptor pathway activation and sensitivity to gefitinib (Iressa) in human pancreatic cancer cell lines Cancer Res 66 3802 3812 10.1158/0008-5472.CAN-05-3753 1:CAS:528:DC%2BD28XjtVOrur8%3D 16585207
18. S Kakiuchi Y Daigo N Ishikawa C Furukawa T Tsunoda S Yano K Nakagawa T Tsuruo N Kohno M Fukuoka S Sone Y Nakamura 2004 Prediction of sensitivity of advanced non-small cell lung cancers to gefitinib (Iressa, ZD1839) Hum Mol Genet 13 3029 3043 10.1093/hmg/ddh331 1:CAS:528:DC%2BD2cXhtVClu7rE 15496427 (Pubitemid 40045258)
19. WK Yip VC Leong MA Abdullah S Yusoff HF Seow 2008 Overexpression of phospho-Akt correlates with phosphorylation of EGF receptor, FKHR and BAD in nasopharyngeal carcinoma Oncol Rep 19 319 328 1:CAS:528:DC%2BD1cXitV2ks78%3D 18202777
20. MJA GM R Pathmanathan N Raab-Traub 2004 Differential signaling pathways are activated in the Epstein-Barr virus-associated malignancies nasopharyngeal carcinoma and Hodgkin lymphoma Cancer Res 64 5251 5260 10.1158/0008-5472.CAN-04- 0538 (Pubitemid 39006545)
21. LSY MK W Xia A Matin Y Wen KY Kwong L Bourguignon MC Hung 2001 Nuclear localization of EGF receptor and its potential new role as a transcription factor Nat Cell Biol 3 802 808 10.1038/ncb0901-802 (Pubitemid 32842685)
22. F Cappuzzo E Magrini GL Ceresoli S Bartolini E Rossi V Ludovini V Gregorc C Ligorio A Cancellieri S Damiani A Spreafico CT Paties L Lombardo C Calandri G Bellezza M Tonato L Crino 2004 Akt phosphorylation and gefitinib efficacy in patients with advanced non-small-cell lung cancer J Natl Cancer Inst 96 1133 1141 1:CAS:528:DC%2BD2cXntFamsbg%3D 15292385 (Pubitemid 39207049)